Patents Assigned to Momenta Pharmaceuticals, Inc.
  • Patent number: 10377832
    Abstract: Modified glycoproteins, and methods of making and using such modified glycoproteins, are described.
    Type: Grant
    Filed: April 25, 2017
    Date of Patent: August 13, 2019
    Assignee: Momenta Pharmaceuticals, Inc.
    Inventors: Nathaniel Washburn, James Meador, III, Carlos J. Bosques, Dorota A. Bulik, Naveen Bhatnagar, Julia Brown, Lynn Markowitz, Sathya Prabbhakar
  • Patent number: 10377809
    Abstract: Sulfated glycoproteins, and methods of making and using such sulfated glycoproteins, are described.
    Type: Grant
    Filed: April 10, 2017
    Date of Patent: August 13, 2019
    Assignee: Momenta Pharmaceuticals, Inc.
    Inventors: Dorota A. Bulik, Carlos J. Bosques, Brian Edward Collins, Maurice Gaston Hains, Nathaniel J. Washburn, James Meador, Sean Smith, Naveen Bhatnagar
  • Publication number: 20190218299
    Abstract: Provided herein are methods for treating fibrosis, including diseases or disorders associated with fibrosis, for example systemic sclerosis.
    Type: Application
    Filed: May 19, 2017
    Publication date: July 18, 2019
    Applicant: Momenta Pharmaceuticals, Inc.
    Inventors: Joel PRADINES, Elma KURTAGIC
  • Patent number: 10317410
    Abstract: A multi-dimensional chromatographic method for the separation of N-glycans. The method comprises providing a glycan preparation that includes at least one negatively charged N-glycan. The glycan preparation is then separated by anion-exchange chromatography and at least one secondary chromatographic technique.
    Type: Grant
    Filed: April 6, 2017
    Date of Patent: June 11, 2019
    Assignee: Momenta Pharmaceuticals, Inc.
    Inventors: Ian Christopher Parsons, Ting Zheng, Nur Sibel Gunay, Carlos J. Bosques
  • Patent number: 10266590
    Abstract: The present invention relates to the characterization and production of biologics.
    Type: Grant
    Filed: September 1, 2016
    Date of Patent: April 23, 2019
    Assignee: Momenta Pharmaceuticals, Inc.
    Inventors: Brian Edward Collins, Joseph Glajch, John Robblee
  • Patent number: 10239944
    Abstract: The present invention relates to compositions and methods of engineered IgG Fc constructs, wherein said Fc constructs include one or more Fc domains.
    Type: Grant
    Filed: April 28, 2016
    Date of Patent: March 26, 2019
    Assignee: Momenta Pharmaceuticals, Inc.
    Inventors: Carlos J. Bosques, James S. Huston, Jonathan C. Lansing, Leona E. Ling, James Meador, III, Daniel Ortiz, Laura Rutitzky
  • Publication number: 20190079100
    Abstract: Methods of assessing biosimilarity of proteins, e.g., therapeutic antibodies, are described.
    Type: Application
    Filed: May 6, 2016
    Publication date: March 14, 2019
    Applicants: Momenta Pharmaceuticals, Inc., Momenta Pharmaceuticals, Inc.
    Inventors: Desiree Tsao, James Anderson
  • Publication number: 20190048417
    Abstract: The present invention features methods of treating a subject having an autoimmune disease and/or inflammation including determining the genotype, and/or the glycophenotype of the subject and administering to the subject an Fc-activity modulating agent or an anti-TNF? agent based on the genotype and/or the glycophenotype of the subject. The invention also features methods of predicting the responsiveness of a patient to an anti-TNF? treatment by identifying a patient having inflammation or an autoimmune disease, determining the genotype, or glycophenotype of the subject, and selecting the patient for treatment with an Fc-activity modulating agent or an anti-TNF? agent based on the genotype and/or the glycophenotype of the subject.
    Type: Application
    Filed: September 30, 2016
    Publication date: February 14, 2019
    Applicant: Momenta Pharmaceuticals, Inc.
    Inventors: Nathaniel Washburn, Patrick Halvey, Kevin McConnell, Victor Farutin, Ishan Capila, Leona E. Ling, Anthony Manning
  • Patent number: 10160992
    Abstract: Methods for analyzing, selecting, characterizing or classifying compositions of a co-polymer, e.g., glatiramer acetate are described. The methods entail analysis of pyro-glutamate in the composition, and, in some methods, comparing the amount of pyro-glutamate present in a composition to a reference standard.
    Type: Grant
    Filed: January 3, 2018
    Date of Patent: December 25, 2018
    Assignee: Momenta Pharmaceuticals, Inc.
    Inventors: Xiangping Zhu, Zachary Shriver, Yanjie Jiang, Corinne Bauer, James Eric Anderson, Peter James Ahern
  • Patent number: 10144944
    Abstract: Polypeptide preparations having target levels of glycans, and methods of producing such polypeptide preparations using putrescine, are described.
    Type: Grant
    Filed: April 25, 2017
    Date of Patent: December 4, 2018
    Assignee: Momenta Pharmaceuticals, Inc.
    Inventor: Holly Prentice
  • Patent number: 10023894
    Abstract: Methods of producing recombinant therapeutic fusion proteins described herein can include culturing Chinese hamster ovary (CHO) cells under conditions suitable for expression of a recombinant therapeutic fusion protein including one or more glycans, where the CHO cells have not been genetically engineered to produce terminal alpha-galactosyl residues on glycans; treating the one or more glycans of the recombinant glycoprotein with one or more exoglycosidases; measuring glycans containing terminal galactose-alpha-1-3-galactose residues on the fusion protein by nuclear magnetic resonance (NMR); and producing a recombinant therapeutic fusion protein in the CHO cells if a target level of terminal galactose-alpha-1-3-galactose residues is measured.
    Type: Grant
    Filed: August 21, 2015
    Date of Patent: July 17, 2018
    Assignee: Momenta Pharmaceuticals, Inc.
    Inventors: Carlos J. Bosques, Jennifer Murphy, Hetal Sarvaiya, Nathaniel Washburn, Cuihua Liu, Xiao-Jin Xu
  • Patent number: 10016449
    Abstract: Described herein are pharmaceutical compositions comprising a LMWH preparation having at least one chain having a glycol split uronic acid residue (UG) in the preparation and uses thereof.
    Type: Grant
    Filed: May 27, 2014
    Date of Patent: July 10, 2018
    Assignee: Momenta Pharmaceuticals, Inc.
    Inventors: Kelly Neelon, Gary Mills, James Anderson
  • Patent number: 10017585
    Abstract: Methods and compositions related to promoting hair growth are described.
    Type: Grant
    Filed: June 15, 2011
    Date of Patent: July 10, 2018
    Assignee: Momenta Pharmaceuticals, Inc.
    Inventors: He Zhou, Edward Cochran
  • Patent number: 9933432
    Abstract: A multi-dimensional chromatographic method for the separation of N-glycans. The method comprises providing a glycan preparation that includes at least one negatively charged N-glycan. The glycan preparation is then separated by anion-exchange chromatography and at least one secondary chromatographic technique.
    Type: Grant
    Filed: August 19, 2016
    Date of Patent: April 3, 2018
    Assignee: Momenta Pharmaceuticals, Inc.
    Inventors: Ian Christopher Parsons, Ting Zheng, Nur Sibel Gunay, Carlos J. Bosques
  • Patent number: 9926583
    Abstract: Polypeptide preparations having target levels of glycans, and methods of producing such polypeptide preparations using DMSO, are described.
    Type: Grant
    Filed: October 5, 2016
    Date of Patent: March 27, 2018
    Assignee: Momenta Pharmaceuticals, Inc.
    Inventors: Holly Prentice, Rasheed Tijani, Brett Belongia
  • Patent number: 9921210
    Abstract: Methods and compositions related to high mannose glycans are described.
    Type: Grant
    Filed: April 7, 2011
    Date of Patent: March 20, 2018
    Assignee: Momenta Pharmaceuticals, Inc.
    Inventors: Brian Edward Collins, Jay Duffner, Carlos J. Bosques, Dorota A. Bulik, James Myette, James Meador
  • Patent number: 9914951
    Abstract: Polypeptides having target levels of C-terminal variants are described.
    Type: Grant
    Filed: September 9, 2016
    Date of Patent: March 13, 2018
    Assignee: Momenta Pharmaceuticals, Inc.
    Inventor: Holly Prentice
  • Patent number: 9890410
    Abstract: The present invention provides methods of evaluating a glycoprotein preparation for the absence, presence or amount of an N-acetylhexosamine glycan, e.g., an N-acetylglucosamine glycan.
    Type: Grant
    Filed: September 9, 2015
    Date of Patent: February 13, 2018
    Assignee: MOMENTA PHARMACEUTICALS, INC.
    Inventors: Nathaniel Washburn, Enrique Arevalo, Kevin Millea, Carlos J. Bosques, Jay Duffner, Brian Edward Collins
  • Patent number: 9714898
    Abstract: A method of manufacturing a glatiramer acetate drug product is described. The method entails measuring one or both of alpha helical content of the glatiramer acetate and random coil content of the glatiramer acetate in the batch and manufacturing a glatiramer acetate drug product using at least a portion of the glatiramer acetate when the alpha helical content and or random coil content meets certain criteria.
    Type: Grant
    Filed: August 3, 2015
    Date of Patent: July 25, 2017
    Assignee: Momenta Pharmaceuticals, Inc.
    Inventor: Ramamurthi Sridharan
  • Patent number: 9695244
    Abstract: The present invention relates to the characterization and production of denosumab.
    Type: Grant
    Filed: May 31, 2013
    Date of Patent: July 4, 2017
    Assignee: Momenta Pharmaceuticals, Inc.
    Inventors: John Robblee, Brian Edward Collins, Ganesh Kaundinya, Carlos J. Bosques